Pharsight

Kyowa Kirin patents expiration

1. Nourianz patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7541363 KYOWA KIRIN Microcrystal
Nov, 2024

(5 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7727994 KYOWA KIRIN Methods of treating patients suffering from movement disorders
Jan, 2023

(1 year, 4 months ago)

US8318201 KYOWA KIRIN Method of stabilizing diarylvinylene compound
Sep, 2027

(3 years from now)

US7727993 KYOWA KIRIN Administering adenosine A2A receptor antagonist to reduce or suppress side effects of parkinson's disease therapy
Jan, 2028

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 27, 2024

Drugs and Companies using ISTRADEFYLLINE ingredient

NCE-1 date: 28 August, 2023

Market Authorisation Date: 27 August, 2019

Treatment: A method of reducing off time from l-dopa therapy, comprising administering, to a human patient with parkinson's disease, an effective amount of istradefylline, wherein the patient currently receives ...

Dosage: TABLET;ORAL

More Information on Dosage

NOURIANZ family patents

Family Patents